

# Presentation of proposed board members

The Nomination Committee's proposal AGM 2017 (item 11 in the proposed agenda)



**New election of:**

**Jan Törnell**

*Born:* 1960

*Education:* Associate professor in Physiology, Faculty of Medicine, Gothenburg University. Medical degree from Gothenburg University.

*Other ongoing assignments:* Adjunct Professor, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University. Chairman of the Board of LIDDS AB, Glactone Pharma AB and Glactone Pharma Development AB. Director of the Board at Stayble AB and Diaprost AB. CEO at Oncorena AB and Innoext AB. Partner in P.U.L.S. AB.

*No of shares in NeuroVive:* -

*Other:* Non-affiliated to the Company, the management and to major owners.

Jan Törnell, born 1960, is Associate Professor and Medical doctor with 20 years experience from different senior positions within the pharmaceutical industry, both in Sweden and internationally. Jan has held the position as Vice President in AstraZeneca Oncology & Infection 2009-2011 and Vice President Translational Science 2006-2008. He was Director at AstraZeneca Discovery 1999-2005 and Astra 1996-1999. Jan is Editor-in-Chief for *Drug Discovery Today – Disease Models* published by Elsevier. Principal supervisor of several students resulting in PhD theses. Author of 80 scientific publications and innovator on 6 patents.



**New election of:**

**David Bejker**

*Born:* 1975

*Education:* Master of Science in Business and Economics from Stockholm School of Economics.

*Other ongoing assignments:* -

*No of shares in NeuroVive:* -

*Other:* Non-affiliated to the Company, the management and to major owners.

David Bejker is the CEO of Affibody Medical AB, a company that develops innovative biopharmaceuticals, since 2008. He has many years of industry experience both from an investor perspective, through employment in HealthCap, and also operating as a business developer of Affibody AB during 2003 to 2005. David Bejker has been CEO of Affibody in a period when the company successfully focused its strategy to become a financially strong biopharmaceutical company with projects in clinical development and a large number of global licensing and collaboration deals. Affibody has under his leadership also secured major grants from the EU, the NCI and Vinnova.



**Re-election of:**

**Gregory Batcheller**

Chair since 2008 and Director since 2000.

*Born:* 1957

*Education:* LL.M., Lund University, J.D., University of Toronto and B.Sc.(Econ.), London School of Economics.

*No. of shares in NeuroVive:* 404 332 shares (including family) and 1,74 percent of the shares in Maas Biolab LLC, owner of 3 874 432 shares in NeuroVive.

*Other assignments:* Chair of Monocl AB and Xintela AB, managing director of Stanbridge Corporation BVBA (Belgium) and Director of Business Research Life Sciences Ltd (United Kingdom) and Director of Saga Diagnostics AB.

*Other:* Affiliated to the Company and the management. Non-affiliated to major owners.



**Re-election of:**

**Marcus Keep**

Director (2000)

*Born:* 1959

*Education:* BSc in Chemistry from University of South Carolina. BA in Religion from Dartmouth College. MD from Medical University of South Carolina. Neurosurgery speciality training from Montreal Neurological Institute, McGill University.

*Ongoing assignments:* CEO and chair of Maas Biolab LLC (USA) and CEO of Keep Enterprises, LLC (USA) and Restorative Neurosurgery Foundation (USA).

*No. of shares in NeuroVive:* 425 929 shares (including family) and shares in Maas Biolab LLC (owner of 3 874 432 shares in NeuroVive) where Marcus Keep controls 48.44 percent of the shares.

*Other:* Non-affiliated to the Company, the management and to major owners.



**Re-election of:**

**David Laskow-Pooley**

Director (2016)

*Born:* 1954

*Education:* BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP., Sunderland School of Pharmacy.

*No. of shares in NeuroVive:* -

*Other assignments:* CEO and board member of LondonPharma Ltd and member of the board of TapImmune Inc, USA, OBN Ltd, England, England, ProtoPharma Ltd, England and Pharmafor Ltd, England.

*Other:* Non-affiliated to the Company, the management and to major owners.